Gastroenterology Clinical Trials List


A 52-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase III Study with Re-Randomization at Week 25 To Evaluate the Efficacy and Safety of Oral Ibodutant 10mg Once Daily in Female Patients with Irritable Bowel Syndrome with Diarrhea

Type of Disease:

Irritable bowel syndrome (IBS) with diarrhea

Locations Available:

Concorde Medical Group
232 East 30th Street
New York, NY 10016

Principal Investigator:

Inessa Khaykis, MD


Lily Alaj


Return to the Gastroenterology Clinical Trials List.